[Form 4] GENPACT LIMITED Insider Trading Activity

Rhea-AI Filing Summary

Genpact Limited (G) insider transaction: Sameer Dewan, Senior Vice President, reported selling 20,078 common shares on 08/28/2025 at $45 per share, leaving him with 89,148 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The filing shows a direct disposition of shares and does not disclose any derivative transactions or a 10b5-1 plan.

Positive

• Transparent disclosure of transaction date, price ($45) and shares sold (20,078)
• Form 4 filed and signed (attorney-in-fact) indicating compliance with Section 16 reporting

Negative

• No disclosure of a 10b5-1 trading plan or stated reason for the sale, leaving intent unspecified

Insights

Securities Analyst

TL;DR: Insider sold a meaningful block, reducing direct holdings but still retaining a sizeable stake.

The sale of 20,078 shares at $45 is a clear, reported disposal that reduces Sameer Dewan's direct stake to 89,148 shares. For a securities analyst, this is a routine executive liquidity event documented on Form 4 and provides transparent price and quantity details. There is no accompanying information in the filing about the reason for the sale or any pre-arranged trading plan, and no derivative activity was reported.

Corporate Governance Expert

TL;DR: Properly executed Form 4 filing shows compliance; absence of a noted 10b5-1 plan leaves intent unspecified.

From a governance perspective the Form 4 appears properly executed and timely, with an attorney-in-fact signature. The filing documents a direct sale and the remaining beneficial ownership; however, it does not indicate that the transaction was made pursuant to a Rule 10b5-1 trading plan. That omission means observers cannot confirm whether the sale was pre-planned, which is often relevant to interpreting insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dewan Sameer

(Last) (First) (Middle)

C/O GENPACT LLC

521 FIFTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NY 10175

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Genpact LTD [ G ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/28/2025		S		20,078	D	$45	89,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Thomas D. Scholtes, as Attorney-in-fact for Sameer Dewan	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Sameer Dewan report on the Form 4 for Genpact (G)?

He reported a sale of 20,078 common shares on 08/28/2025 at a price of $45 per share, leaving 89,148 shares owned.

Does the Form 4 for Genpact (G) show any option or derivative transactions?

No. Table II for derivative securities is blank and the filing discloses only a non-derivative common share sale.

Was the sale by Sameer Dewan reported as part of a 10b5-1 trading plan?

The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan.

When was the Form 4 for this transaction signed?

The filing shows a signature by an attorney-in-fact on 08/29/2025.

How many shares does Sameer Dewan hold after the reported sale?

The Form 4 reports 89,148 common shares beneficially owned following the sale.